恩度联合复方苦参注射液治疗晚期非小细胞肺癌恶性胸腔积液的效果

摘要
图/表
参考文献(20)
相关文章 (5)

全文: PDF (320 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的观察重组人血管内皮抑制素（恩度）联合复方苦参注射液治疗晚期非小细胞肺癌（NSCLC）恶性胸腔积液的临床效果和不良反应。方法选取武汉大学人民医院2015年6月～2017年6月晚期NSCLC合并恶性胸腔积液患者68例，按随机数字表法分为治疗组和对照组，各34例。对照组胸腔内注入恩度30 mg，1周后重复给药1次，治疗组在此基础上用250 mL氯化钠注射液稀释复方苦参注射液20 mL后静滴，1次/d，连用14 d为1个疗程。治疗1个月后观察临床疗效和不良反应。结果治疗组客观缓解率及疾病控制率明显高于对照组，差异有统计学意义（P ＜ 0.05）。两组患者的不良反应主要是恶心、呕吐、乏力及骨髓抑制，主要为Ⅰ～Ⅱ度不良反应，差异无统计学意义（P ＞ 0.05）。结论恩度联合复方苦参注射液治疗晚期NSCLC恶性胸腔积液疗效显著，且不良反应小，具有较为积极的临床使用价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	宋军俊戈伟▲

关键词 ：恩度, 复方苦参注射液, 非小细胞肺癌, 恶性胸腔积液

Abstract：Objective To evaluate the efficacy and adverse reactions of recombinant human endostatin (Endostar) combined with compound Kushen Injection in the treatment of advanced non-small cell lung cancer (NSCLC) malignant pleural effusion. Methods Sixty-eight cases of advanced NSCLC patients with malignant pleural effusion from June 2015 to June 2017 in People's Hospital of Wuhan University were randomly divided into treatment group and control group, with 34 patients in each group. In the control group, 30 mg of Endostar was injected into the thoracic cavity and repeated once a week later. On the basis of this, the treatment group was diluted 20 mL of compound Kushen Injection with 250 mL of Sodium Chloride Injection and intravenously instilled once a day, 14 days was used as a course of the treatment. After one month of treatment, the clinical efficacy and adverse reactions were observed. Results The objective remission rate and disease control rate in the treatment group were significantly higher than the control group, the differences were statistically significant (P ＜ 0.05). Adverse reactions of the two groups were mainly nausea, vomiting, fatigue and myelosuppression. The main adverse reactions were grade Ⅰ to Ⅱ, the differences were not statistically significant (P ＞ 0.05). Conclusion The efficacy of Endostar combined with compound Kushen Injection in the treatment of advanced NSCLC malignant pleural effusion was significant, and little adverse reactions, with a relatively positive clinical value.

Key words： Endostar Compound Kushen injection Non-small cell lung cancer Malignant pleural effusion

基金资助:国家重点研发计划项目（2016YFC1303800）。

通讯作者: ▲通讯作者

引用本文:

宋军俊戈伟▲. 恩度联合复方苦参注射液治疗晚期非小细胞肺癌恶性胸腔积液的效果[J]. 中国医药导报, 2018, 15(11): 143-146.
SONG Junjun GE Wei▲ . The efficacy of Endostar combined with compound Kushen Injection in the treatment of advanced non-small cell lung cancer malignant pleural effusion. 中国医药导报, 2018, 15(11): 143-146.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2018/V15/I11/143

[1] Porcel JM，Aureli E，Manuel V，et al. Etiology of pleural effusions：analysis of more than 3，000 consecutive thoracenteses [J]. Arch Bronconeumol，2014，50（5）：161-165.
[2] Segal A，Sterrett GF，Frost FA，et al. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology： results of a 20 year audit [J]. Pathol，2013，45（1）：44-48.
[3] Call S，Sánchez D，Ramiporta R. Diagnosis and Treatment of Malignant Pleural Effusion [J]. Malignant Effusions，2012：23-55.
[4] Chen Y，Liang B，Zhao YJ，et al. Transcription expression and clinical significance of vascular endothelial growth factor mRNA and endostatin mRNA in pleural effusions of patients with lung cancer [J]. Diagn Cytopathol，2012，40（4）：287-291.
[5] Ferician O，Cimpean AM，Avram S，et al. Endostatin Effects on Tumor Cells and Vascular Network of Human Renal Cell Carcinoma Implanted on Chick Embryo Chorioallantoic Membrane [J]. Anticancer Res，2015，35（12）：6521-6528.
[6] Dresler CM，Olak J，Herndon JE，et al. Phase Ⅲ intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion [J]. Chest，2015，127（3）：909-915.
[7] Pratesi V，La CC，Bartolozzi G. Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clin?鄄ical trials networks [J]. J Clin Oncol，2007，25（32）：5070-5077.
[8] Heffner JE，Nietert PJ，Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions [J]. Chest，2000，117（1）：79-86.
[9] Cusumano G，Margaritora S，Porziella V，et al. Malignant pleural effusion [J]. Annali Italiani Di Chirurgia，2007，78（5）：389-391.
[10] Grove CS，Lee YC. Vascular endothelial growth factor：the key mediator in pleural effusion formation [J]. Curr Opin Pulm Med，2002，8（4）：294-301.
[11] Yano S，Herbst RS，Shinohara H，et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation [J]. Clin Cancer Res，2000，6（3）：957-965.
[12] Matsumori Y，Yano S，Goto H，et al. ZD6474，an inhibitor of vascular endothelial growth factor receptor tyrosine kinase，inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model [J]. Oncol Res，2006，16（1）：15-26.
[13] Ferician O，Cimpean AM，Avram S，et al. Endostatin Effects on Tumor Cells and Vascular Network of Human Renal Cell Carcinoma Implanted on Chick Embryo Chorioallantoic Membrane [J]. Anticancer Res，2015，35（12）：6521-6528.
[14] Li ZN，Yuan ZF，Mu GY，et al. Augmented anti-angiogenesis activity of polysulfated heparin-endostatin and polyethylene glycol-endostatin in alkali burn-induced corneal ulcers in rabbits [J]. Exp Ther Med，2015，10（3）：889-894.
[15] Zhang D，Wu J，Liu S，et al. Network meta-analysis of Chinese herbal injections combined with the chemotherapy for the treatment of pancreatic cancer [J]. Medicine，2017， 96（21）：e7005.
[16] 林洪生.恶性肿瘤中医诊疗指南[M].北京：人民卫生出版社，2014：21-24.
[18] 张伯礼.中药注射剂临床合理使用手册[M].武汉：中国中医药出版社，2016：32-35.
[19] 张敬伟，段冬梅，任中海. 复方苦参注射液与顺铂腹腔灌注化疗联合治疗胃癌恶性腹水[J].中国实验方剂学杂志，2016（11）：179-183.
[20] 刘玲，钟世寿，李国苗. 复方苦参注射液联合顺铂治疗恶性胸腔积液疗效及不良反应观察[J].现代肿瘤医学，2017，25（2）：230-233.